BluGlass has landed a A$1.4 million Phase II deal with Uviquity, extending their collaboration on cutting-edge photonic integrated circuits and visible GaN lasers.
- A$1.4 million contract for Phase II photonics development
- Focus on wafer processing, packaging, and laser integration
- Uviquity’s deep-UV PIC platform targets sensing and disinfection
- Potential for long-term manufacturing supply agreement
- Phase II follows successful completion of Phase I milestones
Extension of Strategic Photonics Partnership
BluGlass Limited (ASX:BLG) has secured a A$1.4 million (US$1 million) Phase II contract from Uviquity, deepening their existing Joint Development Agreement. This new phase will expand BluGlass’ role beyond research into wafer and chip processing, advanced packaging, and laser integration, alongside purchases of its visible gallium nitride (GaN) lasers.
The deal builds on the successful completion of Phase I, which advanced Uviquity’s aluminum nitride (AlN) photonic integrated circuit (PIC) platform. Uviquity recently unveiled the world’s first chip-scale deep-UV laser at 229 nm, a breakthrough targeting analytical, sensing, and far-UVC disinfection applications across semiconductor, pharmaceutical, environmental, and defence sectors.
Technology and Market Focus
Uviquity’s AlN PIC platform is at the forefront of photonics innovation, delivering chip-based deep-UV light sources that serve emerging markets for human-safe disinfection and precision sensing. Phase II will see BluGlass apply its expertise in visible GaN laser processing and packaging to support Uviquity’s roadmap, potentially enabling next-generation quantum and disinfection technologies.
Jim Haden, BluGlass CEO, emphasised the strategic value of this collaboration: "Uviquity is leveraging our visible laser processing and advanced packaging expertise to expand its unique aluminum nitride platform into sensing, quantum and disinfection applications." He also highlighted the potential for a long-term manufacturing supply agreement as Uviquity moves towards commercialisation.
Commercial and Financial Implications
The A$1.4 million Phase II commitment will be paid in instalments starting in Q3 2026, reflecting confidence in BluGlass’ manufacturing capabilities and development pipeline. Uviquity CEO Scott Burroughs noted the partnership’s technical milestones, including the world-first deep-UV laser, and described Phase II as a shift from R&D to product-focused activities.
This contract adds to BluGlass’ growing portfolio of development deals, following recent capital raises aimed at scaling GaN laser production and expanding its photonics footprint. The collaboration with Uviquity not only underpins near-term revenue but also positions BluGlass within fast-growing photonics segments with strong commercial potential.
Bottom Line?
BluGlass’ Phase II contract with Uviquity marks a pivotal step from R&D towards commercial photonic products, setting the stage for future supply agreements and market expansion.
Questions in the middle?
- How will BluGlass’ visible GaN lasers integrate with Uviquity’s AlN PIC platform at scale?
- What milestones will define progress and trigger payments in the Phase II contract?
- Could this partnership catalyse BluGlass’ entry into quantum sensing and far-UVC disinfection markets?